Tags

Type your tag names separated by a space and hit enter

The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Expert Rev Vaccines. 2015; 14(9):1167-79.ER

Abstract

With an estimated 68,000 cases each year, Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia. Vaccination against the disease is recommended for endemic populations and also for travelers at risk. Recently, a Vero cell-derived, inactivated, SA14-14-2 strain-based JE vaccine (JE-VC) became available for travelers from non-endemic regions, replacing the traditional mouse brain-derived vaccines. First licensed in 2009, JE-VC is currently available in Europe, the USA, Canada, Australia and several other countries. In 2013, the vaccine was approved by the European Medicines Agency and the US Food and Drug Administration for use in children. This review summarizes current data on the immunogenicity, safety and clinical use of JE-VC.

Authors+Show Affiliations

Haartman Institute, University of Helsinki, Helsinki, Finland.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26162529

Citation

Erra, Elina O., and Anu Kantele. "The Vero Cell-derived, Inactivated, SA14-14-2 Strain-based Vaccine (Ixiaro) for Prevention of Japanese Encephalitis." Expert Review of Vaccines, vol. 14, no. 9, 2015, pp. 1167-79.
Erra EO, Kantele A. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev Vaccines. 2015;14(9):1167-79.
Erra, E. O., & Kantele, A. (2015). The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Review of Vaccines, 14(9), 1167-79. https://doi.org/10.1586/14760584.2015.1061939
Erra EO, Kantele A. The Vero Cell-derived, Inactivated, SA14-14-2 Strain-based Vaccine (Ixiaro) for Prevention of Japanese Encephalitis. Expert Rev Vaccines. 2015;14(9):1167-79. PubMed PMID: 26162529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. AU - Erra,Elina O, AU - Kantele,Anu, Y1 - 2015/07/10/ PY - 2015/7/12/entrez PY - 2015/7/15/pubmed PY - 2016/5/3/medline KW - Ixiaro KW - JE-VC KW - Japanese encephalitis KW - Japanese encephalitis vaccine KW - immunogenicity KW - safety KW - traveler SP - 1167 EP - 79 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 14 IS - 9 N2 - With an estimated 68,000 cases each year, Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia. Vaccination against the disease is recommended for endemic populations and also for travelers at risk. Recently, a Vero cell-derived, inactivated, SA14-14-2 strain-based JE vaccine (JE-VC) became available for travelers from non-endemic regions, replacing the traditional mouse brain-derived vaccines. First licensed in 2009, JE-VC is currently available in Europe, the USA, Canada, Australia and several other countries. In 2013, the vaccine was approved by the European Medicines Agency and the US Food and Drug Administration for use in children. This review summarizes current data on the immunogenicity, safety and clinical use of JE-VC. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/26162529/The_Vero_cell_derived_inactivated_SA14_14_2_strain_based_vaccine__Ixiaro__for_prevention_of_Japanese_encephalitis_ L2 - http://www.tandfonline.com/doi/full/10.1586/14760584.2015.1061939 DB - PRIME DP - Unbound Medicine ER -